[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chonnam National University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":350},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,52,78,108,135,162,195,222,246,272,300,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641603","abbreviated-antithrombotic-therapy-after-pci-in-patients-with-af-and-ami-100641603",false,"NCT07583784","Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI","Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction","HERO-AF-AMI","Inclusion Criteria:\n\n1. Patients aged 19 years old\n2. Patients with AF and CHA2DS2-VA score ≥2.\n3. ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)\n\n   * STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12\n   * NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12\n\n     1. Symptoms of ischemia.\n     2. New or presumed new significant ST-T wave changes\n     3. Development of pathological Q waves on electrocardiography.\n     4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.\n     5. Intracoronary thrombus detected on angiography.\n4. Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.\n\nExclusion Criteria:\n\n1. Patients contraindicated for use of DOACs or clopidogrel\n2. Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist\n3. Planned cardiac surgery within 1 year after randomization\n4. Patients with severe thrombocytopenia or coagulopathy\n5. Liver cirrhosis or severe hepatic dysfunction\n6. Advanced chronic kidney disease (creatinine clearance \\\u003C15 ml\u002Fmin\u002F1.73 m2) or on dialysis\n7. Prior history of intracranial hemorrhage\n8. Coexisting conditions related to high risk of life-threatening bleeding\n9. Pregnancy or breast feeding\n10. Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n11. Unwillingness or inability to comply with the procedures described in this protocol.","ALL","19 Years",{"count":20,"type":21},860,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).",[27,28,29,30],"Myocardial Infarction (MI)","ST-Segment Elevation Myocardial Infarction(STEMI)","NSTEMI - Non-ST-Segment Elevation Myocardial Infarction","AF - Atrial Fibrillation",[32,33,34,35,36,37,38],"AF","Myocardial infarction","STEMI","NSTEMI","DOAC","NOAC","OAC alone","NOT_YET_RECRUITING","2026-06-15",{"date":42,"type":43},"2026-06-17","ACTUAL",{"date":45,"type":21},"2026-07-01",{"date":47,"type":21},"2032-12-31",{"name":49,"class":50},"Chonnam National University Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100589461","late-lumen-changes-after-drug-coated-balloon-angioplasty-versus-drug-eluting-stents-in-de-novo-coronary-lesions-100589461","NCT06954714","Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions","LARGER-DCB","Inclusion Criteria\n\n1. Subject must be at least 19 years of age\n2. Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily\n3. Patients with at least one lesion with greater than 50% diameter stenosis or fractional flow reserve ≤0.80 requiring revascularization in de-novo coronary artery of reference vessel size ≥3.0 mm\n\nExclusion Criteria\n\n1. Patients unable to provide consent\n2. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents\n3. Patients with angiographic findings of 1) Left main coronary artery disease 2) In-stent restenosis is the cause of target lesion 3) Target lesion in bypass graft 4) True bifurcation lesion that requires upfront 2-stenting\n4. Patients who have non-cardiac co-morbid conditions with life expectancy \\\u003C1 year\n5. Patients who may result in protocol non-compliance (site investigator's medical judgment)\n6. Patients with cardiogenic shock or cardiac arrest\n7. Patients with severe left ventricular systolic dysfunction (ejection fraction \\\u003C30%)\n8. Patients with severe valvular heart disease requiring open heart surgery\n9. Pregnant or lactating women",{"count":60,"type":21},256,[24],"This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).",[64],"Coronary Artery Disease",[66,67],"drug-coated balloon","intravascular ultrasound","RECRUITING","2026-05-08",{"date":71,"type":43},"2026-05-12",{"date":73,"type":43},"2025-08-18",{"date":75,"type":21},"2028-12-31",{"name":49,"class":50},8,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":51},"100460207","coronary-microvascular-dysfunction-assessments-in-myocardial-infarction-with-non-obstructive-coronary-arteries-100460207","NCT05272618","Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","Clinical Relevance of Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","CMD-MINOCA","Inclusion Criteria:\n\n* Subject with age ≥19 years and acute myocardial infarction\n\n  * Rise and\u002For fall of cardiac troponin with one level \\>99 percentile plus ischemic signs\u002Fsymptoms\n\n    * Subject with non-obstructive coronary arteries\n  * \\\u003C50% diameter stenosis or\n  * fractional flow reserve (FFR) \\>0.80 ③ Subject without previous history of coronary artery disease\n\n    * Subject who performed invasive coronary angiography within 24 hours after presentation ⑤ Subject who eligible for invasive and non-invasive coronary physiologic assessment\n\nExclusion Criteria:\n\n* Subject with obstructive coronary arteries\n\n  * Subject with alternate diagnosis including sepsis, pulmonary embolism, myocarditis, Takotsubo syndrome, spontaneous coronary dissection, and other cardiomyopathies.\n\n    * Subject with cardiogenic shock or cardiac arrest ④ Subject who has non-cardiac co-morbid conditions with life expectancy \\\u003C1 year ⑤ Subject or lactating women ⑥ Subject unable to provide consent",{"count":87,"type":21},150,"12 Months","OBSERVATIONAL","To compare clinical outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) according to the coronary microvascular dysfunction (CMD), evaluated by optical coherence tomography (OCT), invasive and non-invasive coronary physiologic assessment.",[92,93,94],"Myocardial Infarction","Coronary Microvascular Dysfunction","Vasospasm, Coronary",[96,97,98,99,100,101],"MINOCA","Coronary physiology","Cardiac PET","CFR","IMR","OCT",{"date":71,"type":43},{"date":104,"type":43},"2022-02-14",{"date":106,"type":21},"2030-12-31",{"name":49,"class":50},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100533587","oct-versus-angiography-for-culprit-lesion-revascularization-in-acute-myocardial-infarction-patients-100533587","NCT06227754","OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts","Randomized Controlled Trial of Optical Coherence Tomography Versus Angiography for Culprit Lesion Revascularization in Patients With Acute Myocardial Infarction","FRAME-AMI3","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Acute ST-segment elevation myocardial infarction (STEMI)\n\n  \\*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1\n* Primary percutaneous coronary intervention (PCI) in \\\u003C 12 h after the onset of symptoms for STEMI patients\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Target lesions not amenable for PCI by operators' decision\n* Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)\n* Creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)\n* Cardiogenic shock (Killip class IV) at presentation\n* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus\n* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)\n* Pregnancy or breast feeding\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Unwillingness or inability to comply with the procedures described in this protocol",{"count":117,"type":21},1500,[24],"The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).",[121,92],"ST Elevation Myocardial Infarction",[123,124,125,126],"ST-segment elevation MI","Optical coherence tomography","Intravascular imaging","Primary PCI","2026-05-05",{"date":69,"type":43},{"date":130,"type":43},"2024-03-25",{"date":132,"type":21},"2031-12-31",{"name":49,"class":50},18,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":51},"100636226","assessing-catecholamine-treatment-initiation-options-norepinephrine-vs-dopamine-for-cardiogenic-shock-100636226","NCT07562932","Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock","ACTION-CS","Inclusion Criteria: 1\\&2\n\n1. Age ≥ 19\n2. Cardiogenic shocka in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D\n\n   * Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)\n\n     1. systolic blood pressure \\\u003C90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \\>90 mm Hg And\n     2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography\n   * Patients will be further classified based on the SCAI shock classification system as follows:\n\n     1. SCAI B: no signs of hypoperfusion\n     2. SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml\u002Fhour) or lactate over 2.0mmol\u002FL\n     3. SCAI D: requirement of second-line vasoactive drug or mechanical circulatory support based on the predefined treatment protocol\n\nExclusion Criteria: any of these,\n\n1. Administration of vasoactive drug more than 6 hours before enrollment\n2. Patients already on temporary mechanical circulatory supportb before enrollment\n3. Glasgow Coma Scale lower than 8 or other evidence of irreversible brain injury\n4. Shock etiologies other than cardiogenic which include postcardiotomy shock or mixed shock\n5. Pregnancy or lactation",{"count":143,"type":21},512,[24],"The goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are:\n\nDoes norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine?\n\nDoes norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest?\n\nResearchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment.\n\nParticipants will:\n\nBe randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug\n\nReceive treatment and monitoring based on current clinical guidelines for cardiogenic shock\n\nUndergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization\n\nBe followed for outcomes at 1 month, 6 months, and 1 year after enrollment\n\nThis study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.",[147],"Cardiogenic Shock",[149,150,151,152,153],"Vasoactive drug","Norepinephrine","Dopamine","Randomized controlled trial","Cardiogenic shock","2026-04-28",{"date":156,"type":43},"2026-05-01",{"date":158,"type":21},"2026-05-31",{"date":160,"type":21},"2032-05-31",{"name":49,"class":50},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":51},"100436864","timing-of-ffr-guided-pci-for-non-ira-in-nstemi-and-mvd-option-nstemi-100436864","NCT04968808","Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)","OPtimal TIming of Fractional Flow Reserve-Guided Complete RevascularizatiON in Non-ST-Segment Elevation Myocardial Infarction (OPTION-NSTEMI)","Inclusion Criteria:\n\n1. Age ≥ 19 years old\n2. Non-ST-segment elevation myocardial infarction\n\n   * Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and,\n\n     * occurs at rest, usually lasting \\> 10 minutes\n     * severe and new onset (within the prior 4-6 weeks)\n     * crescendo pattern\n   * Elevated cardiac biomarkers and,\n\n     * ≥ 99% value of high-sensitivity cardiac troponin\n   * No ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or newly developed left bundle branch block on 12-lead electrocardiogram\n3. PCI within 72 hours after symptom development\n4. Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation\n5. Patient's or protector's agreement about study design and the risk of PCI\n\nExclusion Criteria:\n\n1. Cardiogenic shock at initial presentation or after treatment of IRA\n2. TIMI flow at non-IRA ≤ 2\n3. Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision\n4. Non-IRA lesion not suitable for PCI treatment by operators' decision\n5. Chronic total occlusion at non-IRA\n6. History of anaphylaxis to contrast agent\n7. Pregnancy and lactation\n8. Life expectancy \\\u003C 1-year\n9. Severe valvular disease\n10. History of CABG, or planned CABG\n11. Fibrinolysis before admission",{"count":170,"type":21},1014,[24],"Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention \\[PCI\\] for both infarct-related artery \\[IRA\\] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.",[174,175,176],"Myocardial Infarction, Acute","Multi-Vessel Coronary Artery Stenosis","Multi Vessel Coronary Artery Disease",[178,179,175,180,181,182,183,184,185,186],"Non-ST-Segment Elevation Myocardial Infarction","Multi-Vessel Coronary Artery Disease","Culprit-Only","Multi-Vessel Percutaneous Coronary Intervention","Percutaneous Coronary Intervention","Complete Revascularization","Timing","Staged Percutaneous Coronary Intervention","Fractional Flow Reserve","2026-04-22",{"date":189,"type":43},"2026-04-27",{"date":191,"type":43},"2021-09-01",{"date":193,"type":21},"2028-08-31",{"name":49,"class":50},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},"100593109","timing-of-coronary-angiography-in-nstemi-complicated-by-acute-hf-100593109","NCT07002164","Timing of Coronary Angiography in NSTEMI Complicated by Acute HF","Trial of IMmediate Invasive Versus Delayed Coronary ANGiography in Non-ST-Segment Elevation Myocardial Infarction Complicated by Acute Decompensated Heart Failure: The TIMING-AHF Trial","TIMING-AHF","Inclusion Criteria:\n\n* Age ≥19 years\n* Non-ST-segment elevation myocardial infarction\n* New-onset or worsening of dyspnea (New York Heart Association class ≥2)\n* Pulmonary congestion\n* Patient's or guardian's consent after understanding the study\n\nExclusion Criteria:\n\n* Cardiogenic shock at initial presentation\n* ST-segment elevation myocardial infarction\n\n  * ST-segment elevation ≥0.1 mV in at least 2 contiguous leads, or\n  * New onset left bundle branch block\n  * Posterior wall myocardial infarction\n* Refractory angina\n* Life threatening ventricular arrhythmias\n* Life expectancy \\\u003C1 year\n* Apparently non-ischemic cause of HF\n* Pregnancy and lactation\n* History of coronary artery bypass grafting (CABG), or planned CABG\n* Patient's refusal to participate in study",{"count":204,"type":21},780,[24],"Study objectives:\n\nTo determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF). The primary objective of this trial is to test the hypothesis that immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.\n\nStudy hypothesis:\n\nImmediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.\n\nBackground:\n\nAlthough current guidelines recommend early CAG within 2 hours for patients with NSTEMI complicated by AHF, many patients with NSTEMI complicated by AHF did not receive early CAG. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF. Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG \\\u003C2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.\n\nStudy procedure:\n\nFollowing the establishment of NSTEMI diagnosis, participants fulfilling the eligibility criteria will be randomized at a ratio of 1:1 to immediate CAG ≤2 hours after randomization or delayed CAG after stabilization on another day during hospitalization.",[27,208],"Heart Failure",[210,211,212,184],"Non-ST-segment elevation myocardial infarction","Acute decompensated heart failure","Coronary angiography","2026-03-17",{"date":215,"type":43},"2026-03-19",{"date":217,"type":43},"2025-07-15",{"date":219,"type":21},"2032-04-30",{"name":49,"class":50},20,{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":51},"100630019","long-term-clinical-outcomes-after-retinal-artery-occlusion-100630019","NCT07482228","Long-term Clinical Outcomes After Retinal Artery Occlusion","Long-Term Cardiovascular and Cerebrovascular Outcomes After Retinal Artery Occlusion: A Nationwide Study","CVO-RAO","Inclusion Criteria:\n\n* Patients newly diagnosed with retinal artery occlusion\n\nExclusion Criteria:\n\n* Patients with a prior diagnosis of retinal artery occlusion before the study period.\n* Patients diagnosed with giant cell arteritis.",{"count":231,"type":21},15000,"Retinal artery occlusion (RAO) is a rare but vision-threatening vascular disorder that is commonly caused by embolic events originating from the heart or carotid arteries. Patients with RAO are known to have an increased risk of subsequent cardiovascular and cerebrovascular events, including ischemic stroke and myocardial infarction. However, long-term outcomes and optimal medical treatment strategies for these patients remain insufficiently characterized.\n\nThe purpose of this nationwide population-based study is to investigate the incidence of long-term cardiovascular and cerebrovascular outcomes in patients diagnosed with retinal artery occlusion using the Korean National Health Insurance Service (NHIS) database. In addition, the study aims to evaluate the impact of various medical therapies, including antiplatelet agents, anticoagulants, and statins, on long-term clinical outcomes.",[234],"Retinal Artery Occlusion",[236,237,238],"RAO","CRAO","BRAO","2026-03-16",{"date":215,"type":43},{"date":242,"type":43},"2026-03-01",{"date":244,"type":21},"2027-08-31",{"name":49,"class":50},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":253,"maxAge":4,"enrollmentInfo":254,"targetDuration":256,"studyType":89,"phases":4,"briefSummary":257,"conditions":258,"keywords":261,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":51},"100448806","imaging-and-physiologic-evaluation-of-coronary-artery-disease-100448806","NCT05124249","Imaging and Physiologic Evaluation of Coronary Artery Disease","Imaging and Physiologic Evaluation of Coronary Artery Disease: a Prospective Registry Study (IP-CAD)","Inclusion Criteria:\n\n* Subject must be at least 18 years of age\n* Subjects who suspected ischemic heart disease and underwent ICA.\n* Subjects who were performed intravascular imaging or invasive physiologic assessment\n\nExclusion Criteria:\n\n* Subject with Age \\\u003C18 years\n* Pregnant women","18 Years",{"count":255,"type":21},2000,"3 Years","To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease (CAD) undergoing invasive coronary angiography (ICA), intravascular imaging, or invasive physiologic assessment.",[259,260],"Ischemic Heart Disease","Atherosclerosis",[182,262,263,264,265],"Intravascular Imaging","Intravascular Ultrasound","Optical Coherence Tomography","Fractional flow reserve",{"date":267,"type":43},"2026-03-18",{"date":269,"type":43},"2021-11-01",{"date":106,"type":21},{"name":49,"class":50},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":279,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":4},"100622964","effectiveness-of-artificial-intelligence-integrated-mixed-reality-based-high-alert-medications-management-simulation-program-100622964","NCT07390461","Effectiveness of Artificial Intelligence Integrated Mixed Reality-based High-Alert Medications Management Simulation Program","AIMR-HAM","Inclusion Criteria:\n\n* Nurses with at least one to six years of clinical experience.\n\n  * Those who understand the purpose and procedures of this study and have given written consent to participate.\n\n    * Those who have no physical or cognitive limitations in using mixed reality devices.\n\n      ④ Those who are able to communicate in Korean and understand and respond to questions.\n\nExclusion Criteria:\n\n* Those who do not wish to participate in the study. ② Those who have participated in education related to high-alert medications within the past six months.\n\n  * Those who are unable or have difficulty participating in the mixed reality education program due to visual, hearing, or neurological impairments, or adverse effects such as dizziness or motion sickness.\n\n    * Those who voluntarily withdraw from the study midway through.",true,{"count":281,"type":21},60,[24],"The goal of this clinical trial is to learn if a Artificial Intelligence integrated Mixed Reality-based High-Alert Medications Management Simulation Program (AIMR-HAM) helps hospital nurses manage high-alert medicines (HAMs) more safely. MR mixes real and virtual elements to let nurses practice in realistic scenarios.\n\nThe main questions are:\n\nDoes the AIMR-HAM improve nurses' medication safety skills? Does the AIMR-HAM lower medication errors and improve clinical performance?\n\nResearchers will compare two groups to answer these questions:\n\nIntervention group: AIMR-HAM Control group: standard education only\n\nWho can take part:\n\nNurses who work at large hospitals and have 1 to 6 years of clinical experience.\n\nAbout 60 nurses will join the study.\n\nWhat participants will do:\n\nAttend the assigned training (AIMR-HAM or standard education only). Complete short tests and surveys before and after training to measure skills, communication, and clinical reasoning.\n\nReport any medication errors that occur during the study. Why this matters: The study will show whether AIMR-HAM training can improve how nurses handle HAMs and make patient care safer.",[285],"Healhty",[287,288,289,290,291],"High-alert medications","nurse","mixed reality","artificial intelligence","medication safety","2026-01-28",{"date":294,"type":43},"2026-02-05",{"date":296,"type":21},"2026-03-04",{"date":298,"type":21},"2026-03-06",{"name":49,"class":50},{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":51},"100520265","psychopharmacotherapy-for-depressive-patients-100520265","NCT06054321","Psychopharmacotherapy for Depressive Patients","A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients","BMDD-2022","Inclusion Criteria:\n\n* 19 to 65 years\n* Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder by study psychiatrists\n* Score≥17 on Hamilton Depression Rating Scale-17\n* With ability to understand the objective of the study and sign informed consent\n* Initiation of an antidepressant treatment for the current episode or no psychotropics excluding sleep pills or benzodiazepines within 1 month of participation\n\nExclusion Criteria:\n\n* Current or lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, or other psychotic disorders\n* current major depressive disorder with psychotic features\n* History of organic psychosis, epilepsy, or seizure disorder\n* Current anorexia nervosa or obsessive compulsive disorder\n* Unstable or uncontrolled medical condition\n* Unable to complete the psychiatric assessment or comply with the medication regimen due to a severe physical illness\n* History of anticonvulsant treatment\n* Electroconvulsive therapy for the current depressive episode\n* Hospitalization for any psychiatric diagnosis except depressive disorder (e.g., alcohol\u002Fdrug dependence)\n* severly high risk of suicide, self-harm or homicide by investigator's assessment\n* Pregnant or breastfeeding\n* lack of treatment information on the current depressive episode","65 Years",{"count":310,"type":21},400,[24],"The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.",[314],"Major Depressive Disorder",[316,317,318,319],"depression","antidepressant monotherapy","stepwise psychopharmacotherapy","multimodal serum biomarker score","2024-04-16",{"date":322,"type":43},"2024-04-18",{"date":324,"type":43},"2022-08-03",{"date":106,"type":21},{"name":49,"class":50},{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":334,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100413055","laparoscopic-vs-open-distal-gastrectomy-after-neoadjuvant-chemotherapy-100413055","NCT04658589","Laparoscopic vs. Open Distal Gastrectomy After Neoadjuvant Chemotherapy","A Multicenter Prospective Phase II Comparative Study of Laparoscopic Versus Open Distal Gastrectomy After Neoadjuvant Chemotherapy for the Treatment of Locally Advanced Gastric Cancer Patients","Inclusion Criteria:\n\n1. Patients who voluntarily expressed their consent to participate in this trial by signing a written 'Subject Consent Form.'\n2. Patients whose gastric adenocarcinoma located in the middle or lower part of the stomach is histologically confirmed and deemed possible to perform a radical distal gastrectomy surgery.\n3. Patients who come under T2\u002FN(+)M0, T3\\~4a\u002FN(- or +) M0 according to the 8th edition of the TNM classification.\n\nExclusion Criteria:\n\n* Methodologies\n\n  1. Patients less than 20 years old or older than 80 years old\n  2. Eastern Cooperative Oncology Group(ECOG) ≥ 2\n  3. Patients with a surgery experience due to a neoplasm in the stomach.\n  4. Patients with complications due to gastric cancer (acute hemorrhage, gastric outlet obstruction or perforation)\n  5. Patients with distant metastases (M1) including distant lymph nodes (Retropancreatic, para-aortic, periportal, retroperitoneal, or mesenteric lymph nodes)\n  6. Patients without distant metastases but who are, according to a surgeon's judgment, unqualified for radical gastrectomy because of invasions to adjacent organs (T4b).\n  7. In the case of localized conglomerated metastatic lymph nodes\n  8. Patients who received surgery or radiation therapy for a primary cancer developed in another organ or those with active\u002Fsynchronous double cancer in recent 5 years.\n  9. Patients who participated in another clinical trial or was administered with a different investigational drug in 30 days prior to randomization.\n  10. Patients who had any of the following in 6 months before the trial recruitment: myocardial infarction, severe\u002Funstable angina pectoris, coronary\u002Fperipheral artery bypass surgery, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack.\n  11. Patients with a previous experience of uncontrolled seizure, central nervous system or psychological disorders whose conditions are clinically significant to the extent that they are unable to express consent to participate in the trial and oral drug administration is not possible.\n  12. Patients with uncontrolled active infection or sepsis.\n  13. Patients who had deep vein thrombosis in recent 4 weeks before the beginning of the trial recruitment.\n  14. Patients with serious acute or chronic disease that can degrade the patient's ability to participate in the trial or impede the interpretation of the trial results.\n  15. Pregnant or breast-feeding patients. Fertile female patients who are positive in pregnancy test.\n\n      Drug Administration for Neoadjuvant Chemotherapy\n  16. Inadequate functions of marrow or organs:\n\n      I. Absolute Neutrophil Count (ANC) \\\u003C 1.5 x 109\u002FL II. Platelet (PLT) \\\u003C 100 x 109\u002FL III. Hemoglobin (Hb) ≤ 9 g\u002FdL IV. AST\\> 2.5 x ULN, ALT\\> 2.5 x ULN V. ALP \\> 2.5 x ULN VI. Total Bilirubin (T. Bil) \\> 1.5 x ULN VII. Serum creatinine (Cr) \\> 1.5 x ULN\n  17. Patients who have peripheral neuropathy with clinical signs of Grade≥2 (NCI CTCAE v4.03) or with absence of deep tension reflex (DTR).\n  18. Patients with hypersensitivity history of the investigational drug (5-FU, Oxaliplatin, Docetaxel).\n  19. Patients who are on treatment with warfarin or coumarin anticoagulants.\n  20. Patients who are on immunosuppressive therapy.\n  21. Patients who are receiving co-medication with Cytochrome P450 2A6 inducer, inhibitor, and substrate.","20 Years","80 Years",{"count":337,"type":21},238,[24],"The study was designed as single-country, multi-center, open-labelled, randomized (1:1), phase II trial.\n\n238 patients with medically and technically operable advanced gastric adenocarcinoma in middle or distal 1\u002F3 of stomach are enrolled and randomly assigned to laparoscopic gastrectomy group and open gastrectomy group. 4 cycles of mFLOT chemotherapy will be conducted before and after gastrectomy.\n\nThe primary objective of this study is comparison of D2 lymph node dissection compliance rate between open surgery group and laparoscopic surgery group after neoadjuvant chemotherapy.",[341],"Stomach Neoplasm","2020-12-07",{"date":344,"type":43},"2020-12-08",{"date":346,"type":21},"2021-01",{"date":348,"type":21},"2026-12",{"name":49,"class":50},""]